BULLETIN: Kansas Regulatory Commission's Staff Recommends Westar Rate Cut; No Effect On Rating Sep 05

  • ID: 2040431
  • September 2005
  • Region: Kansas
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) Sept. 9, 2005--Standard & Poor's Ratings Services said today that the recommendation by the staff of the Kansas Corporation Commission (KCC) in Westar Energy Inc.'s (BB+/Positive/-) pending rate case, which is not binding on KCC, will not affect the rating on Westar. Although the staff has endorsed important ratemaking principles, with modifications, the $41.5 million (6.9%) rate cut for Westar's southern region and an $11.2 million (2.1%) rate hike for the northern region fall significantly short of Westar's request. The company is seeking a $47.8 million (9.3%) increase for the company's northern region and $36.3 million (6.3%) for the southern area. A final KCC order is expected in December 2005. Should the KCC embrace the...

Companies mentioned in this report are: Westar Energy Inc.
Action: Bulletin

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Westar Energy Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.